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Protein N-glycosylation reactions form a distributed reaction network spanning over different compartments of 
Golgi apparatus. The resulting glycan structures are influenced by glycosylation enzymes, the supply rate of 
nucleotide sugars, as well as competition among extending glycan substrates for a common enzyme and among 
different enzymes for a common substrate. Controlling the glycan profile of a therapeutic protein product is 
important for product quality for both innovative drugs as well as biosimilars. Metabolic engineering of the 
glycosylation pathway offers a venue for modulating the glycan profile. We have taken a systems engineering 
approach to identify, through model assisted design, the genetic manipulations that may steer the glycan flux to 
the desired path. However, unlike the energy metabolism pathway for which a small number of enzymes play 
pivotal roles in controlling the flux, the glycosylation pathway lacks key regulated steps as easily identifiable 
targets for genetic alteration to re-direct the flux. The model prediction thus serves only as a imprecise guide 
rather than a clear beacon. Furthermore, very likely multiple genetic alterations are needed in order to steer 
glycan flux distribution. A scheme of rapid construction of gene combinations to facilitate genetic engineering of 
the cell is necessary. 
 
We establish a golden gate assembly workflow for production of multi-gene constructs for engineering the 
glycan biosynthesis pathway. Libraries containing promoters of varying strengths, terminators, and glycosylation 
related coding sequences of interest, all refactored to be devoid of type IIS restriction sites, were synthesized. In 
the first level of assembly, an additional library of single gene constructs were formed from these base 
components with single reactions. In the second level of assembly, these monocistrons were then 
combinatorically combined to form a multi-gene cassette library.  
 
In an application of this approach, the N-glycosylation pattern of a recombinant IgG produced in CHO cells was 
examined with a stoichiometric network visualization tool (GlycoVis) to track the reaction paths which lead to the 
product glycans and identify galactosylation as potentially limiting glycan maturation. Cassettes consisting of 
sequences coding for nucleotide sugar synthesis enzymes, nucleotide sugar transporters, and 
glycosyltransferases were then selected to engineer the IgG producing cell. Multiple cassettes successfully 
directed the glycosylation to produce antibody with desirable glycoforms. These results served to refine our 
model parameters and sharpen its predictive capabilities. This combination of systems analysis and synthetic 
glycoengineering can be broadly applied and enhances our capability to steer N-Glycan patterns and control the 
quality of therapeutic proteins.  
 
 
